Key Points
- Insider sale: Director Andrew Hollman Meyer sold 3,333 shares on Dec. 1 at an average price of $32.98 for about $109,922, reducing his stake by 3.77%; this follows prior sales of 3,333 shares on Nov. 14 and 16,665 shares on Oct. 28.
- Recent results: Janux reported a better-than-expected quarter with EPS of ($0.39) vs. consensus ($0.60) and revenue of $10.0 million versus an expected $3.07 million.
- Market view: The stock has a MarketCap of ~$1.03B, a MarketBeat consensus rating of "Moderate Buy" with an average target of $62.67, and institutional investors hold about 75.39% of the shares.
Janux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) insider Andrew Hollman Meyer sold 3,333 shares of the company's stock in a transaction on Monday, December 1st. The stock was sold at an average price of $32.98, for a total transaction of $109,922.34. Following the completion of the transaction, the insider owned 84,974 shares of the company's stock, valued at $2,802,442.52. This trade represents a 3.77% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.
Andrew Hollman Meyer also recently made the following trade(s):
- On Friday, November 14th, Andrew Hollman Meyer sold 3,333 shares of Janux Therapeutics stock. The shares were sold at an average price of $30.00, for a total value of $99,990.00.
- On Tuesday, October 28th, Andrew Hollman Meyer sold 16,665 shares of Janux Therapeutics stock. The stock was sold at an average price of $30.06, for a total value of $500,949.90.
Janux Therapeutics Trading Up 7.9%
Shares of Janux Therapeutics stock opened at $17.11 on Thursday. The firm has a market capitalization of $1.03 billion, a PE ratio of -10.18 and a beta of 2.82. Janux Therapeutics, Inc. has a 12 month low of $15.51 and a 12 month high of $71.71. The business's 50-day moving average price is $27.03 and its 200-day moving average price is $25.31.
Janux Therapeutics (NASDAQ:JANX - Get Free Report) last released its earnings results on Thursday, November 6th. The company reported ($0.39) earnings per share for the quarter, topping analysts' consensus estimates of ($0.60) by $0.21. The firm had revenue of $10.00 million during the quarter, compared to the consensus estimate of $3.07 million. As a group, analysts predict that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Janux Therapeutics
Several hedge funds and other institutional investors have recently modified their holdings of the stock. US Bancorp DE raised its stake in Janux Therapeutics by 2,402.9% in the first quarter. US Bancorp DE now owns 1,727 shares of the company's stock worth $47,000 after buying an additional 1,658 shares in the last quarter. Osaic Holdings Inc. grew its holdings in shares of Janux Therapeutics by 704.6% during the 2nd quarter. Osaic Holdings Inc. now owns 3,468 shares of the company's stock worth $80,000 after acquiring an additional 3,037 shares during the period. Virtus Investment Advisers LLC grew its holdings in shares of Janux Therapeutics by 37.9% during the 2nd quarter. Virtus Investment Advisers LLC now owns 3,679 shares of the company's stock worth $85,000 after acquiring an additional 1,011 shares during the period. Tower Research Capital LLC TRC raised its position in shares of Janux Therapeutics by 175.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 3,928 shares of the company's stock worth $91,000 after acquiring an additional 2,502 shares in the last quarter. Finally, Ameritas Investment Partners Inc. lifted its stake in shares of Janux Therapeutics by 25.6% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,020 shares of the company's stock valued at $93,000 after purchasing an additional 820 shares during the period. Hedge funds and other institutional investors own 75.39% of the company's stock.
Wall Street Analyst Weigh In
JANX has been the subject of a number of research reports. Bank of America cut their price objective on shares of Janux Therapeutics from $58.00 to $49.00 and set a "buy" rating for the company in a research note on Tuesday. Barclays upped their price target on shares of Janux Therapeutics from $47.00 to $48.00 and gave the company an "overweight" rating in a research report on Friday, November 7th. Wolfe Research started coverage on Janux Therapeutics in a report on Tuesday, November 18th. They issued a "peer perform" rating on the stock. Piper Sandler assumed coverage on Janux Therapeutics in a report on Monday, August 18th. They set an "overweight" rating and a $42.00 target price for the company. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Janux Therapeutics in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $62.67.
View Our Latest Analysis on JANX
About Janux Therapeutics
(
Get Free Report)
Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
